Skeletal Research Center, Department of Biology, Case Western Reserve University, Cleveland, Ohio 44106, USA.
Stem Cells Transl Med. 2012 Apr;1(4):279-88. doi: 10.5966/sctm.2011-0011. Epub 2012 Apr 2.
Human marrow-derived mesenchymal stem cells (hMSCs) have been investigated for more than 20 years. They have been shown to be therapeutic in a number of animal models and are currently in use in more than 200 clinical trials, thus documenting their importance in the field of translational medicine. Standard protocols for the passage and collection of hMSCs involve trypsinization of preconfluent cultures. This practice is based, at least in part, on concerns that the multipotency of these cells would be diminished if the cultures became confluent. To test this concern, hMSCs were isolated and maintained in standard culture conditions in primary culture and were then subcultured after 2 weeks. The resulting first passage cultures were divided into two groups: those that were subcultured at the normal frequency, usually at 7 days for each passage (referred to as standard conditions [SC]), and those that were maintained for up to 53 days without being further subcultured (extended first passage [EFP]). At the end of the second passage and each of five subsequent subcultures for cells in SC (i.e., through passage 7), complementary EFP cultures were also trypsinized. Cells from each group were counted, resuspended in serum-free medium, and assayed to determine the ability of the cells to differentiate along osteogenic, chondrogenic, and adipogenic lineages. Cells in SC experienced an average of 27 population doublings through seven passages, whereas hMSCs in EFP achieved approximately 16 population doublings after 34 days but demonstrated very little increase in cell number after that time. The ability of hMSCs in EFP to produce bone in ceramic cubes implanted subcutaneously in immunocompromised mice and to differentiate into cartilage in pellet or aggregate culture was at least equivalent to that of the cells in SC through seven passages, whereas the capacity of the EFP hMSCs to produce lipid droplets in adipogenic conditions was maintained but was diminished relative to that of SC cells.
人骨髓间充质干细胞(hMSCs)已经被研究了 20 多年。它们在许多动物模型中被证明具有治疗作用,并且目前正在 200 多项临床试验中使用,这证明了它们在转化医学领域的重要性。hMSCs 传代和收集的标准方案涉及到对预汇合培养物进行胰蛋白酶消化。这种做法至少部分基于这样一种担忧,即如果培养物达到汇合状态,这些细胞的多能性将会降低。为了验证这一担忧,hMSCs 被分离并在原代培养中在标准培养条件下培养,然后在第 2 周进行传代培养。得到的第一代培养物分为两组:一组按正常频率传代,通常每代 7 天(称为标准条件[SC]),另一组在不进一步传代的情况下维持长达 53 天(延长第一代[EFP])。在第 2 代和第 7 代传代的 SC 细胞(即通过第 7 代)中的每个后续传代结束时,也对相应的 EFP 培养物进行胰蛋白酶消化。对每组细胞进行计数、悬浮于无血清培养基中,并进行检测,以确定细胞沿成骨、软骨和成脂谱系分化的能力。SC 中的细胞经历了 7 代的平均 27 个倍增,而 EFP 中的 hMSCs 在 34 天后实现了大约 16 个倍增,但在此之后细胞数量几乎没有增加。EFP 中的 hMSCs 植入免疫缺陷小鼠皮下的陶瓷块中产生骨的能力以及在球体或聚集培养物中分化为软骨的能力至少与通过 7 代传代的 SC 细胞相当,而 EFP hMSCs 在成脂条件下产生脂滴的能力得以维持,但相对于 SC 细胞有所减弱。